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CLINICAL HISTORY:
CLINICAL HISTORY
A 36year old female patient came to the clinic with complaint of enlargement of abdomen for
2 weeks and a sudden increase in weight from 60 kgs to 65.7 kgs in 2 weeks.
MENSTRUAL HISTORY
▪

Normal menstrual cycle

▪

No dysmenorrhea

▪

No menorrhagia

▪

No clots passed

OBSTETRIC HISTORY
▪

Obstetric score – G2P2A0L2 – Both LSCS

▪

Last Child – 14 years old

▪

LMP – 6/11/20
21/10/20
7/9/20

PAST HISTORY
The patient has no significant past history
No previous history of surgeries
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She has no history of diabetes mellitus, hypertension, thyroid, respiratory, cardiac or
connective tissue abnormalities

EXAMINATION AND INVESTIGATIONS:
General physical examination
The female patient was conscious, alert, cooperative and was well nourished, moderately
built was well oriented to time, place and person.
▪

No Pallor

▪

No Icterus

▪

No Cyanosis

▪

No Clubbing

▪

No Lymphadenopathy

▪

No Oedema

▪

Blood pressure-110/80

▪

Pulse – 85 beats / min

SYSTEMIC EXAMINATION
CVS – S1, S2 heard
RS- B/L normal
PER ABDOMEN
On Inspection – No Bulge was seen
On Palpation – Firm lump from pelvis till epigastrium was felt
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Bowel sounds are normal
P/V examination – NAD
CNS – No FND
LOWER ABDOMEN USG –

USG revealed a large solid mass along the posterior uterine wall from the cervix to the
epigastrium as described, ovarian in origin D/D large serosal uterine fibroid.
Ultrasound of lower abdomen excluded ovarian tumor

FINAL DIAGNOSIS:
Fibroid uterus
Differential diagnosis
Ovarian tumour
Endometrial cancer
Endometriosis

DISCUSSION:

Treatment:
Patient underwent myomectomy under spinal anesthesia
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Pre Surgery

Fibroid
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Fibroid with uterus

Uterus with fallopian tube and ovaries
Uterine leiomyomas (fibroids or myomas) are benign tumors of the uterus and clinically
apparent in a large part of reproductive aged women.
Clinically, they present with a variety of symptoms:
▪

excessive menstrual bleeding,

▪

dysmenorrhoea and intermenstrual bleeding

▪

chronic pelvic pain

▪

pressure symptoms such as a sensation of bloatedness,

▪

increased urinary frequency
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▪

bowel disturbance

In addition, they may compromise reproductive functions,
▪

possibly contributing to subfertility

▪

early pregnancy loss

▪

later pregnancy complications.[1]

Treatment
▪

Women with asymptomatic fibroids should be reassured that there is no evidence to
substantiate major concern about malignancy and that hysterectomy is not indicated.

▪

Treatment of women with uterine leiomyomas must be individualized based on
symptomatology, size and location of fibroids, age, need and desire of the patient to
preserve fertility or the uterus, the availability of therapy, and the experience of the
therapist.

▪

In women who do not wish to preserve fertility and/or their uterus and who have been
counselled regarding the alternatives and risks, hysterectomy by the least invasive
approach possible may be offered as the definitive treatment for symptomatic uterine
fibroids and is associated with a high level of satisfaction.

▪

Hysteroscopic myomectomy should be considered first-line conservative surgical
therapy for the management of symptomatic intracavitary fibroids.

▪

Surgical planning for myomectomy should be based on mapping the location, size,
and number of fibroids with the help of appropriate imaging.

▪

When morcellation is necessary to remove the specimen, the patient should be
informed about possible risks and complications, including the fact that in rare cases
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fibroid(s) may contain unexpected malignancy and that laparoscopic power
morcellation may spread the cancer, potentially worsening their prognosis.
▪

Anemia should be corrected prior to proceeding with elective surgery. (II-2A)
Selective progesterone receptor modulators and gonadotropin-releasing hormone
analogues are effective at correcting anemia and should be considered preoperatively
in anemic patients.

▪

Use of vasopressin, bupivacaine and epinephrine, misoprostol, peri-cervical
tourniquet, or gelatin-thrombin matrix reduce blood loss at myomectomy and should
be considered.

▪

Uterine artery occlusion by embolization or surgical methods may be offered to
selected women with symptomatic uterine fibroids who wish to preserve their uterus.
Women choosing uterine artery occlusion for the treatment of fibroids should be
counselled regarding possible risks, including the likelihood that fecundity and
pregnancy may be impacted.

▪

In women who present with acute uterine bleeding associated with uterine fibroids,
conservative management with estrogens, selective progesterone receptor modulators,
antifibrinolytics, Foley catheter tamponade, and/or operative hysteroscopic
intervention may be considered, but hysterectomy may become necessary in some
cases. In centres where available, intervention by uterine artery embolization may be
considered.[2]

Attempts at a nonsurgical treatment of uterine leiomyomas probably began hundreds of years
ago, but scientifically validated modalities became available only some 40 years ago.During
this relatively short period of time, several regimens were introduced using different
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categories of drugs. Today, the most promising belong to two categories: PR modulators and
orally active GnRHR blockers.[3]
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